OncoMatch/Clinical Trials/NCT06379113
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Is NCT06379113 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including GnRH antagonist and Letrozole 2.5mg for endometrial neoplasms.
Treatment: GnRH antagonist · Letrozole 2.5mg — To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Endometrial Cancer
Disease stage
Excluded: Stage MYOMETRIAL INVASION, EXTRAUTERINE METASTASIS
Grade: G1
well-differentiated EEC G1 without myometrial invasion; No signs of suspicious extrauterine involvement
Demographics
Prior therapy
Must have received: progestin (megestrol acetate, medroxyprogesterone acetate, levonorgestrel intrauterine system (LNG-IUS)) — first-line
Using progestin, any of the following therapy, as first-line treatment: 1. Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not 2. Medroxyprogesterone acetate ≥ 250 mg qd using, combined with LNG-IUS inserted or not 3. LNG-IUS inserted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06379113 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received progestin.
Is there an age limit?
Yes. Patients must be 45 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages